Skip to Content

Lixte Biotechnology Holdings Inc LIXT

Morningstar Rating
$2.46 +0.08 (3.38%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LIXT is trading at a 81% premium.
Price
$2.46
Fair Value
$5.74
Uncertainty
Extreme
1-Star Price
$45.79
5-Star Price
$4.59
Economic Moat
Kkhb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LIXT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.38
Day Range
$2.362.61
52-Week Range
$1.589.50
Bid/Ask
$2.22 / $2.73
Market Cap
$5.53 Mil
Volume/Avg
7,517 / 563,814

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
4

Valuation

Metric
LIXT
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
LIXT
Quick Ratio
7.38
Current Ratio
7.75
Interest Coverage
−239.62
Quick Ratio
LIXT

Profitability

Metric
LIXT
Return on Assets (Normalized)
−99.51%
Return on Equity (Normalized)
−1,552.82%
Return on Invested Capital (Normalized)
−108.60%
Return on Assets
LIXT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCzbngnwqsmVdrx$586.1 Bil
VRTX
Vertex Pharmaceuticals IncCpzykcmcFtnyq$113.7 Bil
REGN
Regeneron Pharmaceuticals IncLcddbyqMqqrkkr$108.2 Bil
MRNA
Moderna IncBsfzlyvYyq$50.9 Bil
ARGX
argenx SE ADRPpfmckrNrmg$22.0 Bil
BNTX
BioNTech SE ADRXjnlqpszYsbg$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncBkxpjjyyfBkzqt$18.9 Bil
BMRN
Biomarin Pharmaceutical IncVbscxcsrGfbknpl$14.6 Bil
INCY
Incyte CorpMmhjxscfnRjymjf$12.8 Bil
RPRX
Royalty Pharma PLC Class ATnnjfyswzyJcjtpx$12.3 Bil

Sponsor Center